First FDA-Approved Non-Hormonal Therapy for Hot Flashes Available
Noven announced that Brisdelle (paroxetine) capsules are now available for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot flashes.
Brisdelle, a low-dose selective serotonin reuptake inhibitor (SSRI), is the first non-hormonal therapy approved to treat VMS. Prior to Brisdelle, hormone therapy was the only approved treatment for vasomotor symptoms associated with menopause. Brisdelle is not an estrogen, and its exact mechanism of action for the treatment of vasomotor symptoms is unknown.
Brisdelle is available in 7.5mg strength capsules in 30-count blister packs. This is a lower dose of paroxetine than is indicated for any other condition.
For more information call (800) 455-8070 or visit Brisdelle.com.